Description

Autotaxin-In-3 is a potent and selective small-molecule inhibitor of the autotaxin (ATX) enzyme, a key regulator of lysophosphatidic acid (LPA) production. This compound is crucial for fundamental research into the ATX-LPA signaling axis, which is implicated in a wide range of physiological and pathological processes, including fibrosis, inflammation, and cancer metastasis. It is an essential research tool for pharmaceutical R&D teams, academic institutions, and biotechnology companies focused on oncology, inflammatory diseases, and metabolic disorders.

Application

• Biochemical Research: Used as a selective probe to study the enzymatic activity, structure, and biological function of autotaxin (ATX) in vitro.
• Drug Discovery & Development: Serves as a reference compound or lead molecule in high-throughput screening (HTS) campaigns and medicinal chemistry programs targeting ATX inhibition.
• Oncology Research: Investigated in cellular and animal models to understand and validate the role of the ATX-LPA pathway in tumor progression, metastasis, and the tumor microenvironment.
• Inflammation & Immunology Studies: Applied in research models to elucidate the contribution of ATX to inflammatory responses, autoimmune diseases, and chronic inflammatory conditions.
• Fibrosis Research: Utilized to explore therapeutic potential in models of organ fibrosis, including pulmonary, hepatic, and renal fibrosis.
• Neurobiology: Employed in studies examining the role of LPA signaling in neuropathic pain, neuroinflammation, and demyelinating diseases.
• Academic & Contract Research: Supplied to universities and CROs for basic scientific research and preclinical contract studies.

Basic Information

Product Name	Autotaxin-In-3
CAS No.	2156655-68-2
Molecular Formula	C₂₉H₂₈N₄O₃
Molecular Weight	480.56 g/mol
Synonyms	ATX Inhibitor 3; Autotaxin Inhibitor 3; (S)-N-(4-(3-(2-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)amino)-2-oxoethyl)-2,4-dioxo-3,4-dihydroquinazolin-1(2H)-yl)phenyl)-4-(4-methylpiperazin-1-yl)benzamide; BCI-2156655-68-2; Autotaxin-IN-3; ATX-IN-3; PF-8380 analog; LPA pathway inhibitor.
EINECS	Contact for details

Quality Control

Our Autotaxin-In-3 is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity, NMR and MS for structural confirmation, and residual solvent analysis, to ensure identity, potency, and consistency. Certificates of Analysis (COA) with detailed chromatographic data are provided to support your research integrity and compliance needs.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store desiccated at -20°C. Allow the product to equilibrate to room temperature before opening to minimize moisture uptake. The product is stable under these conditions for at least two years.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Retention time corresponds to reference standard
Identification (MS)	Consistent with molecular ion [M+H]+
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Complies with ICH guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.